Ascofuranone antibiotic is a promising trypanocidal drug for nagana.

Trypanosoma congolense Trypanosoma vivax antibiotic ascofuranone trypanocide

Journal

The Onderstepoort journal of veterinary research
ISSN: 2219-0635
Titre abrégé: Onderstepoort J Vet Res
Pays: South Africa
ID NLM: 0401107

Informations de publication

Date de publication:
08 Feb 2024
Historique:
received: 31 03 2023
accepted: 28 11 2023
revised: 22 11 2023
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: epublish

Résumé

Trypanosomosis is a disease complex which affects both humans and animals in sub-Saharan Africa, transmitted by the tsetse fly and distributed within the tsetse belt of Africa. But some trypanosome species, for example, Trypanosoma brucei evansi, T. vivax, T. theileri and T. b. equiperdum are endemic outside the tsetse belt of Africa transmitted by biting flies, for example, Tabanus and Stomoxys, or venereal transmission, respectively. Trypanocidal drugs remain the principal method of animal trypanosomosis control in most African countries. However, there is a growing concern that their effectiveness may be severely curtailed by widespread drug resistance. A minimum number of six male cattle calves were recruited for the study. They were randomly grouped into two (T. vivax and T. congolense groups) of three calves each. One calf per group served as a control while two calves were treatment group. They were inoculated with 105 cells/mL parasites in phosphate buffered solution (PBS) in 2 mL. When parasitaemia reached 1 × 107.8 cells/mL trypanosomes per mL in calves, treatment was instituted with 20 mL (25 mg/kg in 100 kg calf) ascofuranone (AF) for treatment calves, while the control ones were administered a placebo (20 mL PBS) intramuscularly. This study revealed that T. vivax was successfully cleared by AF but the T. congolense group was not cleared effectively.Contribution: There is an urgent need to develop new drugs which this study sought to address. It is suggested that the AF compound can be developed further to be a sanative drug for T. vivax in non-tsetse infested areas like South Americas.

Identifiants

pubmed: 38426744
doi: 10.4102/ojvr.v91i1.2115
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1-e6

Auteurs

Keisuke Suganuma (K)

National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro. k.suganuma@obihiro.ac.jp.

Classifications MeSH